Fox Run Management’s Atara Biotherapeutics ATRA Stock Holding History

Fox Run Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-958	Closed	-$223K	–	520
2022 Q1	$223K	Buy	+958	New	+$305K	0.12%	377

Other funds holding ATRA

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Fox Run Management's ATRA Position: Q2 2022 in Review

Fox Run Management sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 958 shares — an estimated $223K sold.

Fox Run Management first reported a position in ATRA in Q1 2022 and held it in 1 quarter. The position peaked at $223K in Q1 2022. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

Fox Run Management reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
Fox Run Management sold 958 Atara Biotherapeutics shares in Q2 2022, an estimated $223K.
Fox Run Management first reported a position in Atara Biotherapeutics in Q1 2022 and held it in 1 quarter.
Fox Run Management's Atara Biotherapeutics position peaked at $223K in Q1 2022.
134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on Fox Run Management's 13F filing for Q2 2022, filed 12 Aug 2022.